5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice

Diabetologia

Volumn 45, Issue 1, 2002, Pages 56-65

  Song, X M ^a   Fiedler, M ^b   Galuska, D ^a   Ryder, J W ^a   Fernstrom M ^c   Chibalin, A V ^c   Wallberg Henriksson, H ^a   Zierath, J R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Department of Pharmacology ^*  (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Glucose tolerance; Glucose transport; GLUT4; Glycogen; Glycogen synthase; Hexokinase II; Insulin signalling; Lipids; Myocyte enhancer factor 2; Obesity

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENOSINE PHOSPHATE; FATTY ACID; GLUCOSE TRANSPORTER 4; GLYCOGEN; HEXOKINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCOGEN LIVER LEVEL; GLYCOGEN MUSCLE LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MOUSE; MUSCLE CONTRACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE TOLERANCE TEST; GLYCOGEN; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; LIVER; LIVER GLYCOGEN; MICE; MICE, INBRED C57BL; MICE, OBESE; MUSCLE, SKELETAL; OBESITY; RIBONUCLEOTIDES;

EID: 0036165489     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s125-002-8245-8     Document Type: Article

References (40)

1. Prognosis of diabetics with diabetes onset before the age of 31. I. Survival, causes of death, and complications
2. Obesity, insulin resistance and diabetes: A worldwide epidemic
3. Management of type 2 diabetes: A challenge for patient and physician
4. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus
5. Exercise training in obese diabetic patients
6. Clinical practice recommendations. Diabetes mellitus and exercise
7. Exercise in NIDDM: Are we missing the point?
8. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus
9. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle
10. 5-Aminoimidazole-4-carboxamide ribonucleoside: A specific method for activating protein kinase in intact cells?
11. Inhibition of fatty acid and cholesterol synthase by stimulation of AMP-activated protein kinase
12. Stimulation of rat liver AMP-activated protein kinase by AMP analogues
13. AMP-activated protein kinase, a metabolic master switch: Possible roles in type 2 diabetes
14. Evidence for 5′-AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport
15. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle
16. Effect of AMPK activation on muscle glucose metabolism in conscious rats
17. Metabolic stress and altered glucose transport: Activation of AMP-activated protein kinase as a unifying coupling mechanism
18. Chronic activation of 5′-AMP-activated protein kinase increases GLUT4, hexokinase and glycogen in muscle
19. Increased expression of GLUT4 and hexokinase in rat epitrochlearis muscles exposed to AICAR in vitro
20. Hypoglycaemic effect of AICAriboside in mice
21. Kinetics of 2-deoxyglucose transport in skeletal muscle. Effects of insulin and contractions
22. Reversibility of decreased insulin-stimulated glucose transport capacity in diabetic muscle with in vitro incubation
23. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats
24. Two naturally occurring insulin receptor tyrosine kinase domain mutants provide evidence that phosphatidylinositol 3-kinase activation alone is not sufficient for the meditation of insulin's metabolic and mitogenic effects
25. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus
26. Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients
27. The MEF2A isoform is required for striated muscle-specific expression of the insulin-responsive GLUT4 glucose transporter
28. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse
29. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes
30. 5-Aminoimidazole-4-carboxamide riboside mimics the effect of insulin on the expression of the 2 keygluconeogenic genes PEPCK and glucose-6-phosphatase
31. Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes
32. Evidence from transgenic mice that glucose transport is rate limiting for glycogen deposition and glycolysis in skeletal muscle
33. Overexpression of hexokinase II in transgenic mice
34. Protein-protein interactions in insulin signaling and the molecular mechanisms of insulin resistance
35. Phosphatidylinositol 3-kinase is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation
36. Involvement of phosphoinositide 3-kinase in insulin stimulation of MAP-kinase and phosphorylation of protein kinase-B in human skeletal muscle: Implications for glucose metabolism
37. Inhibition of lipolysis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase
38. Regulation of fatty acid synthesis via phosphorylation of acetyl-CoA carboxylase
39. The AMP-activated protein kinase. Fuel gauge of the mammalian cell?
40. 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes